CLRB

Cellectar Biosciences, Inc. CLRB

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode CLRB GYRE MBRX PULM CYCC AKTX CRVO EVOK
6M -44.63 % 5.85 % -40.74 % -11.67 % -88.90 % -13.08 % -4.00 % 108.64 %
YTD -52.41 % -33.67 % -73.22 % -37.65 % -92.85 % -23.14 % 265.47 % 2.68 %
1Y -92.56 % -40.33 % -80.00 % 126.07 % -96.68 % -65.04 % -40.73 % -9.82 %
3Y -93.03 % -10.06 % -96.84 % 37.86 % -99.86 % -91.07 % -6.21 % -80.48 %
5Y -98.77 % -88.92 % -99.36 % -79.79 % -99.95 % -97.58 % -87.22 % -99.35 %
10Y -99.99 % -99.36 % -99.93 % -99.43 % -100.00 % -99.75 % -99.99 % -99.21 %
From the beginning -100.00 % -99.94 % -99.93 % -99.87 % -100.00 % -99.71 % -100.00 % -99.73 %

Dividend

Gyre Therapeutics, Inc.

Cyclacel Pharmaceuticals, Inc.